Placebo News and Research

RSS

Testosterone patches charge up older women's sex

According to research by an international team of scientists testosterone could recharge the sex lives of older women.

10 Nov 2008

Vitamins C and E do not prevent cardiovascular disease in men

Neither vitamin E nor vitamin C supplements reduced the risk of major cardiovascular events in a large, long-term study of male physicians, according to a study in the November 12 issue of JAMA.

10 Nov 2008

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

VIA Pharmaceuticals, Inc. has announced the results of two Phase 2 studies of its lead drug, VIA-2291.

10 Nov 2008

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids.

10 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

FDA approves Ranexa for the treatment of chronic angina

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.

7 Nov 2008

Beta-alanine supplement shows strong effects in the elderly

Beta-alanine (BA), a dietary supplement widely used by athletes and body builders, has been proven to increase the fitness levels of a group of elderly men and women.

7 Nov 2008

Coping and copulation behavior may help calculate diabetes risk

Discussion of a man's background, attitude, and sexual history isn't just the fodder of Sex and The City episodes - in the future, it could also be a way of evaluating his risk of diabetes.

7 Nov 2008

Saw Palmetto for enlarged prostate

Physician-scientists are studying an herbal supplement that might aid in reducing the symptoms of an enlarged prostate in men. Recent figures show that benign prostatic hyperplasia (BPH) occurs in an estimated 50 percent of men over the age of 50 and in 75 percent of men 80 and older.

6 Nov 2008

Investigational drug, MK-677 shows promise for reducing age-related frailty

Researchers at the University of Virginia Health System report that a daily single oral dose of an investigational drug, MK-677, increased muscle mass in the arms and legs of healthy older adults without serious side effects, suggesting that it may prove safe and effective in reducing age-related frailty.

5 Nov 2008

Safety and efficacy of febuxostat for gout examined

The goal in treating patients with gout is to reduce acute attacks by lowering serum urate levels, which are usually high in this disease.

5 Nov 2008

Folate, vitamin B6 and B12 do not appear to affect cancer risk

A daily supplementation combination that included folic acid and vitamin B6 and B12 had no significant effect on the overall risk of cancer, including breast cancer, among women at high risk of cardiovascular disease, according to a study in the November 5 issue of JAMA, the Journal of the American Medical Association.

5 Nov 2008

Review rubbishing homeopathy discredited

A review published in The Lancet which claimed that homeopathy is just a placebo, has been slammed as seriously flawed in two separate studies.

4 Nov 2008

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

New clinical data show antiviral activity of TMC435, an investigational protease inhibitor (PI) being developed by Tibotec BVBA for the treatment of chronic hepatitis C virus (HCV) infection.

4 Nov 2008

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Medarex, Inc. and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti- C. difficile antibody combination treatment in patients with C.

4 Nov 2008

Two new studies defend homeopathy

Two new studies conclude that a review which claimed that homeopathy is just a placebo, published in The Lancet, was seriously flawed.

4 Nov 2008

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

YM BioSciences Inc. has announced data from two clinical trials of nimotuzumab, its humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). Preliminary results from the two trials which are evaluating nimotuzumab in combination with radiation therapy for the treatment of brain metastases and high-grade gliomas, conducted by YM's licensor, were presented at the 2008 EORTC-NCI-AACR annual meeting recently held in Geneva, Switzerland.

3 Nov 2008

MedImmune starts phase 1/2a clinical trial for respiratory syncytial virus vaccine

MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

3 Nov 2008

Pfizer's Toviaz (fesoterodine fumarate) receives FDA approval for the treatment of overactive bladder

Pfizer Inc has announced that the U.S. Food and Drug Administration (FDA) approved Toviaz (fesoterodine fumarate) extended release tablets for the treatment of overactive bladder (OAB) symptoms.

2 Nov 2008

Cimzia study shows reduction of symptoms and progression of rheumatoid arthritis

UCB has announced pivotal RAPID 1 (RA PreventIon of structural Damage) data published in Arthritis & Rheumatism shows CIMZIA (certolizumab pegol), the only PEGylated anti-TNF (Tumour Necrosis Factor alpha), together with methotrexate (MTX), rapidly reduced symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.

31 Oct 2008

Placebo News and Research

Testosterone patches charge up older women's sex

Vitamins C and E do not prevent cardiovascular disease in men

VIA Pharmaceuticals announces results of phase 2 trials of VIA-2291 in cardiovascular disease

Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

FDA approves Ranexa for the treatment of chronic angina

Beta-alanine supplement shows strong effects in the elderly

Coping and copulation behavior may help calculate diabetes risk

Saw Palmetto for enlarged prostate

Investigational drug, MK-677 shows promise for reducing age-related frailty

Safety and efficacy of febuxostat for gout examined

Folate, vitamin B6 and B12 do not appear to affect cancer risk

Review rubbishing homeopathy discredited

Tibotec presents interim findings for TMC435, investigational hepatitis C treatment

Phase 2 trial of treatment of C-difficile-associated diarrhea shows promise

Two new studies defend homeopathy

YM Biosciences reports on early trials of nimotuzumab in brain metastases and high-grade glioma

MedImmune starts phase 1/2a clinical trial for respiratory syncytial virus vaccine

Pfizer's Toviaz (fesoterodine fumarate) receives FDA approval for the treatment of overactive bladder

Cimzia study shows reduction of symptoms and progression of rheumatoid arthritis

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News